Erratum: Trends in androgen prescribing in the United States, 2001 to 2011 (JAMA Internal Medicine (2013) DOI: 10.1001/jamainternmed.2013.6895);Trends in androgen prescribing in the United States, 2001 to 2011

JAMA Internal Medicine

Volumn 173, Issue 15, 2013, Pages 1465-1466

  Baillargeon, Jacques ^a,b   Urban, Randall J ^a,b   Ottenbacher, Kenneth J ^a,b   Pierson, Karen S ^a   Goodwin, James S ^a,b  

^a University of Texas Medical Branch School of Medicine   (United States)

^b UNIVERSITY OF TEXAS MEDICAL BRANCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN; TESTOSTERONE;

ANDROGEN THERAPY; ERECTILE DYSFUNCTION; FATIGUE; GROUPS BY AGE; HEALTH INSURANCE; HEALTHCARE COMMON PROCEDURE CODING SYSTEM; HUMAN; HYPOGONADISM; LABORATORY TEST; LETTER; PATIENT ATTITUDE; PRIORITY JOURNAL; PSYCHOSEXUAL DISORDER; UNITED STATES;

EID: 84882281522     PISSN: 21686106     EISSN: None     Source Type: Journal    
DOI: 10.1001/jamainternmed.2013.10000     Document Type: Erratum

References (7)

1. Bhasin S, Singh AB, Mac RP, Carter B, Lee MI, Cunningham GR. Managing the risks of prostate disease during testosterone replacement therapy in older men: recommendations for a standardized monitoring plan. J Androl. 2003;24(3): 299-311.
2. US Food and Drug Administration. 2009 Postmarket review. http://www.fda.gov/advisorycommittees/. Accessed December 1, 2012.
3. Basaria S, Coviello AD, Travison TG, et al. Adverse events associated with testosterone administration. N Engl J Med. 2010;363(2):109-122.
4. Calof OM, Singh AB, LeeML, et al. Adverse events associated with testosterone replacement in middle-aged and older men: ameta-analysis of randomized, placebo-controlled trials. J Gerontol A Biol Sci Med Sci. 2005;60(11):1451-1457.
5. Haddad RM, Kennedy CC, Caples SM, et al. Testosterone and cardiovascular risk in men: a systematic review and meta-analysis of randomized placebo-controlled trials. Mayo Clin Proc. 2007;82(1):29-39.
6. Srinivas-Shankar U, Roberts SA, Connolly MJ, et al. Effects of testosterone on muscle strength, physical function, body composition, and quality of life in intermediate-frail and frail elderly men: a randomized, double-blind, placebo-controlled study. J Clin Endocrinol Metab. 2010;95(2):639-650.
7. Wang C, Cunningham G, Dobs A, et al. Long-term testosterone gel (AndroGel) treatment maintains beneficial effects on sexual function and mood, lean and fat mass, and bone mineral density in hypogonadal men. J Clin Endocrinol Metab. 2004;89(5):2085-2098.